Global Patient Derived Xenograft (PDX) Models Market Growth Prospects and Strategic Opportunities Through 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Patient Derived Xenograft (PDX) Models Market?
In recent years, there has been a significant increase in the market size of patient derived xenograft (pdx) models. The market, valued at $0.4 billion in 2024, is projected to reach $0.47 billion in 2025, with a compound annual growth rate (CAGR) of 15.5%. Factors contributing to the growth during the historic period include increased investments in research and development, support from regulatory bodies, numerous partnerships and collaborations, the rise in contract research organizations (CROs), and the growing incidence of cancer cases.
The market size for patient derived xenograft (pdx) models is set to witness substantial growth in the coming years, projected to reach $0.81 billion by 2029, with a compound annual growth rate (CAGR) of 14.9%. This projected growth during the forecast period is attributed to the increase in demand for personalized medicine, a rise in the need for humanized PDX models, an escalating prevalence of cancer, a focus on precision oncology, and increased R&D funds allocated for cancer research. The forecast period will also see major trends such as advancements in technology, an increased demand for humanized PDX models, partnerships in research, increased funding in cancer research, and a heightened emphasis on immuno-oncology.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
Which Growth Drivers Are Shaping The Patient Derived Xenograft (PDX) Models Market Outlook?
The push for personalized medicine is projected to spur the expansion of the patient-derived xenograft (PDX) models market in the future. Personalized medicine customizes medical care to each patient’s unique attributes, considering aspects such as genetics, environment, and lifestyle. Due to advancements in genomics research, which enable bespoke treatments guided by individual genetic make-up, the demand for personalized medicine is on the rise leading to more precise and outcome-oriented healthcare solutions. Patient-derived xenograft (PDX) models support personalized medicine by permitting testing of individual patient tumors to forecast treatment reactions and customize therapies accordingly. For example, in February 2024, the US-based nonprofit umbrella organization, the Personalized Medicine Coalition (PMC), reported that in 2023, the FDA sanctioned 16 new personalized treatments for rare diseases, marking a notable leap from six approvals in 2022. Consequently, the mounting demand for personalized medicine is driving the growth of the patient-derived xenograft (PDX) models market.
What Are The Primary Segmentation Parameters In The Patient Derived Xenograft (PDX) Models Market?
The patient derived xenograft (pdx) modelsmarket covered in this report is segmented –
1) By Type: Mice Models; Rat Models
2) By Technique: Heterotopic Implantation; Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models; Lung Tumor Models; Hematological Tumor Models; Gynecological Tumor Models; Respiratory Tumor Models; Urological Tumor Models; Other Tumor Models
4) By Application: Preclinical Drug Development; Precision Medicine; Co-Clinical Trials; Basic Cancer Research
5) By End-User: Academic And Research Organizations; Contract Research Organizations; Pharmaceutical And Biotechnological Companies; Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice); Humanized Mice Models; Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models; Humanized Rat Models; Genetically Modified Rat Models
Which Emerging Trends Are Reshaping The Patient Derived Xenograft (PDX) Models Market Landscape?
Leading companies in the patient-derived xenograft (PDX) models market are evolving their offerings by creating innovative models that feature in vivo bioluminescence imaging. This technology enables the live tracking of tumor development within the PDX models, which can offer a non-invasive approach to observing tumor metastasis and responses to treatment. This can greatly improve the efficiency of preclinical drug development research. For example, InVitro Research Solutions Private Limited, a Contract Research Organization (CRO) based in India, introduced a novel orthotopic model of human glioblastoma in NSG-SGM3 mice in March 2024. This model, which uses PDX and in vivo bioluminescence imaging, aims to tailor the treatment of glioblastoma, the deadliest and most aggressive type of brain cancer. The use of these models is instrumental in comprehending glioblastoma biology and testing new targeted therapies and immunotherapies, ultimately aiming to enhance patient survival rates.
Which Organizations Are At The Forefront Of The Patient Derived Xenograft (PDX) Models Market?
Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer, Pharmatest Services Ltd., IVRS AB, Altogen Inc
Access The Complete Report Here:
Which Region Holds The Greatest Opportunity For Patient Derived Xenograft (PDX) Models Market Expansion?
North America was the largest region in the patient derived xenograft (PDX) models market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=17226&type=smp
Browse Through More Reports Similar to the Global Patient Derived Xenograft (PDX) Models Market 2025, By The Business Research Company
Patient Simulators Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/patient-simulators-global-market-report
Patient Portal Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/patient-portal-global-market-report
Patient Safety And Risk Management Software Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
